Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 6064-6069, October 15, 2007. doi: 10.1158/1078-0432.CCR-07-0266
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbareschi, M.
Right arrow Articles by Marchetti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbareschi, M.
Right arrow Articles by Marchetti, A.
Related Collections
Right arrowCommentary

Imaging, Diagnosis, Prognosis

Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas

Mattia Barbareschi1, Fiamma Buttitta3, Lara Felicioni3, Sabrina Cotrupi1, Fabio Barassi3, Maela Del Grammastro3, Antonella Ferro2, Paolo Dalla Palma1, Enzo Galligioni2 and Antonio Marchetti3

Authors' Affiliations:1 Unit of Surgical Pathology, Laboratory of Molecular Pathology and 2 Unit of Medical Oncology, S. Chiara Hospital, Trento, Italy, and 3 Clinical Research Center, Center of Excellence on Aging, University-Foundation, Chieti, Italy

Requests for reprints: Antonio Marchetti, Pathology Unit, Clinical Research Center, Center of Excellence on Aging (CeSI), University-Foundation, Via Colle Dell'Ara, 66013 Chieti, Italy. Phone: 39-871-357407/357408; Fax: 39-871-541337; E-mail: amarchetti{at}unich.it.

Purpose: In breast cancer, the PIK3CA gene is frequently mutated at "hotspots" in exons 9 and 20, corresponding to the helical and kinase domains, respectively. We decided to investigate the association of PIK3CA mutations with pathologic features and clinical outcome in a large series of patients with breast cancer.

Experimental Design: Frozen samples from 163 consecutive patients were analyzed for PIK3CA mutations using PCR single-strand conformation polymorphism and sequence analyses.

Results: We identified 46 missense mutations, 24 (53%) in exon 9, and 21 (47%) in exon 20. Twelve (50%) of the 24 mutations in exon 9 were of the E542K type and 11 (46%) were of the E545K type. Twenty (95%) of the 21 mutations in exon 20 were H1047R substitutions. Mutations in exon 9 were more frequent in lobular carcinomas (42% of cases) than in ductal carcinoma (11% of cases; P = 0.002). At univariate survival analysis, PIK3CA exon 20 mutations were associated with prolonged overall and disease-free survival, whereas mutations in exon 9 were associated with significantly worse prognosis. At multivariate analysis, exon 9 PIK3CA mutations were the strongest independent factor to predict poor prognosis for disease-free survival (P = 0.0003) and overall survival (P = 0.001).

Conclusion: Our data show that exon 9 PIK3CA mutations are typical of infiltrating lobular carcinomas. In addition, they indicate that PIK3CA mutations in different exons are of different prognostic value: exon 9 mutations are independently associated with early recurrence and death, whereas exon 20 PIK3CA mutations are associated with optimal prognosis.


Commentary

Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?
Paradiso Angelo, Mangia Anita, Azzariti Amalia, and Tommasi Stefania
Clin. Cancer Res. 2007 13: 5988-5990. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cancer Res.Home page
K. Stemke-Hale, A. M. Gonzalez-Angulo, A. Lluch, R. M. Neve, W.-L. Kuo, M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, et al.
An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
Cancer Res., August 1, 2008; 68(15): 6084 - 6091.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Angelo, M. Anita, A. Amalia, and T. Stefania
Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?
Clin. Cancer Res., October 15, 2007; 13(20): 5988 - 5990.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.